RareCyte operates in the precision medicine market, providing advanced solutions for spatial biology and liquid biopsy. The company serves researchers, translational medicine professionals, and clinical leaders by offering highly multiplexed fluorescent imaging systems, reagents, and contract services. These tools enable the detailed analysis of cell and tissue samples, helping to unlock spatial context for key biomarkers and develop therapeutics and companion diagnostics. RareCyte's business model revolves around selling its proprietary imaging systems and consumables, as well as offering custom assay development services. Revenue is generated through product sales and service contracts. The company's innovative technology, such as the AccuCyte Sample Preparation System, simplifies and standardizes the preparation of blood samples for analysis, enhancing the accuracy and reproducibility of results. RareCyte's solutions are pivotal in advancing research and diagnostics, particularly in understanding complex tumor microenvironments and other critical areas of biomedical research.

Keywords: precision medicine, spatial biology, liquid biopsy, multiplexed imaging, biomarkers, diagnostics, translational medicine, custom assays, AccuCyte, tumor microenvironments.